Pharmacological background of EGFR targeting
Open Access
- 1 July 2004
- journal article
- review article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 15 (7), 1007-1012
- https://doi.org/10.1093/annonc/mdh257
Abstract
Epidermal growth factor receptor (EGFR) signaling pathways play a key role in the regulation of cell proliferation, survival and differentiation. As a consequence, EGFR is one of the best studied ligand–receptor system and specific EGFR inhibition approaches are currently among the most promising and the most advanced in the clinical setting. Monoclonal antibodies (mAbs) and specific tyrosine kinase inhibitors (TKIs) have been developed, among which C225 (Cetuximab) and ZD1839 (Iressa), respectively, are the most advanced. The aim of the present review was not to cover the field of EGFR inhibitors, but to compare at experimental and clinical levels the different key points governing the actions of mAbs and TKIs. In addition, combinations of conventional chemotherapies with EGFR targeting drugs, as well as resistance mechanisms of EGFR targeting, have been reviewed.Keywords
This publication has 28 references indexed in Scilit:
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibodySeminars in Oncology, 2002
- IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancerSeminars in Oncology, 2002
- ZD1839 (IRESSA™): a selective EGFR-TK inhibitorExpert Review of Anticancer Therapy, 2002
- An update on epidermal growth factor receptor inhibitorsCurrent Oncology Reports, 2002
- Receptor tyrosine kinases as targets for anticancer drugsTrends in Molecular Medicine, 2002
- The EGFR family and its ligands in human cancerEuropean Journal Of Cancer, 2001
- The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.Endocrine-Related Cancer, 2001
- Tyrosine Kinase Inhibitors Targeted to the Epidermal Growth Factor Receptor SubfamilyDrugs, 2000
- The Biologic Effects of C225, A Chimeric Monoclonal Antibody to the EGFR, on Human Prostate CarcinomaJournal of Immunotherapy, 1996